Objective-To compare the efficacy, tolerance and safety of 50-150 ,ug orally administered iloprost given twice a day versus placebo in patients with Raynaud's syndrome. Methods-The study was multicentre (n = 3), double blind and placebo controlled. Sixty three patients who had eight or more vasospastic attacks per week were enrolled. After a one week run-in period, all patients received either iloprost or placebo treatment to a maximum tolerated dose of 150 pg twice a day for 10 days.
Results-Patient opinion tended to favour iloprost at the end of the 10 day treatment phase (p = 0.09) and this was significant at day 24 (the follow up visit) (p = 0.011).
Although the duration and severity of attacks tended to decrease in the iloprost treated group, these results tended not to reach statistical significance (for severity p = 0'06 at end of treatment, p = 0-09 on day 24). Conclusion-Iloprost administered intravenously has been shown to be of benefit in the treatment of the Raynaud's syndrome associated with systemic sclerosis, but this route of administration is inconvenient. This study evaluated the use of iloprost administered orally to patients with Raynaud's syndrome. Patient After a washout period of two weeks, during which no medication for relief of Raynaud's symptomatology was taken, patients entered the study. Diary cards were issued and the patients asked to record, on a daily basis, the duration of their Raynaud's attacks in minutes, whether the attack was mild, moderate or severe, and whether it was painful or not. These were completed for a seven day run-in period to ensure that at least eight attacks per week were documented. If an error in completion was detected, this seven day run-in period was repeated. Diary card documentation continued throughout the study period to day 24.
Medication was issued after this run-in period and continued for 10 days. The 10 day limit on treatment duration is a standard limitation imposed by the regulatory authorities on introduction of a novel compound into a patient population. The patients were formally assessed at the start of the 10 day treatment period, at day 3, day 10, and two weeks after the cessation of treatment at day 24. All were inpatients for the first three days and two nights of the study so that side effects could be monitored and blood pressure and pulse rate measured. Blood was taken for routine haematology and biochemistry (urine and electrolytes, liver function tests) on day 0 and day 10 Number of painful attacks as a proportion of all attacks 0 5 (0 3-06) 0 5 (0 3-06) Average severity of attacks on scale 0-3 1-9 (1-6-2-1)
Values are mean (range) except for median age (range).
cation was administered twice a day either at 08:00 and 14:00, or at 14:00 and 20:00. On the first day of treatment patients took one capsule twice, on the second day two capsules twice, and on the third day three capsules twice, corresponding to 50-150 ,ug twice a day or placebo. The greatest tolerated dose was used for the remaining seven days of treatment.
Patients were allocated to receive either iloprost or placebo according to separate computer generated randomisation lists for all three centres.
STATISTICAL ANALYSES
The data were analysed using either the MannWhitney U test or the independent t test, depending on the distribution of the data for continuous variables. The x2 test was used for comparing categorical data between treatment groups. For analysis of the duration of Raynaud's attacks a percentage change from baseline was used. p < 0-05 was considered statistically significant.
Results Table 1 shows that the two groups of patients were comparable in terms of age, gender, and Raynaud's attacks. Additionally, there were six smokers in the placebo group and nine smokers who received iloprost. Table 2 shows drug therapy for RS before the washout period; all medications were stopped before this two week period. Data from all 63 patients were available for the analysis of tolerance and safety data. Fifty three patients were included in the analysis of the efficacy of the drug; the 10 patients (seven placebo, three iloprost) excluded from this analysis failed to complete their diary cards correctly during the treatment phase of the study. Four patients (one placebo, three iloprost) withdrawn during the study had all their available data considered in the analyses; the three iloprost patients were withdrawn because of side effects and the placebo patient because of intercurrent illness.
GLOBAL OPINION
The patients' opinions of treatment are shown in table 2 and in the figure. In the placebo group almost 60% of the patients felt that the symptoms were unchanged or worse after two weeks follow up (day 24). In contrast, more than 60% of the patients who received iloprost felt their condition was improved. The difference between the treatments approached statistical significance (p = 0-09) at the end of treatment (day 10) and was statistically Table 3 shows the percentage change from baseline in the total duration of Raynaud's attacks per week. A greater reduction in mean total duration of attacks was seen in the iloprost group compared with placebo, but the difference did not reach statistical significance.
DURATION AND SEVERITY OF RAYNAUD'S ATACKS
The severity of Raynaud's attacks was assessed by calculating the percentage change in the proportion of painful attacks and the change in average severity of the attacks using the scale: 0 = none; 1 = mild; 2 = moderate; 3 = severe (table 4). Iloprost treatment tended to cause a greater decrease in the number of painful attacks and a greater decrease in the severity of the attacks than placebo. At the end of treatment (day 10) the difference in The pathophysiology of Raynaud's phenomenon is not yet completely understood but is known to include contributions from abnormal neurogenic,'0 blood and blood vessel wall," and immunological and inflammatory responses.'2 13 The discovery that PGI2, produced by the vascular endothelium, is a potent vasodilator and inhibitor of platelet aggregation led to interest in the role of prostanoids in the treatment of RS. Such theoretical considerations were later supported by the finding of the anti-white'4 and anti-red'5 blood cell and fibrinolytic activities'6 of prostacylin-all effects which might be expected to be useful in RS. Intravenous prostaglandins do appear to produce some benefit,6 7 but they can be difficult to use and are understandably less popular with patients than oral medications. Human volunteer studies with a new formulation of iloprost suitable for oral testing showed that, with the slow release preparation, 80% of the active substance was absorbed in the first hour, with a time to maximum plasma concentrations between 60 and 90 minutes.
After a dose of 150 pg, therapeutic plasma concentrations were obtained for a period of 3-3 (SD 1.0) hours. The present study was undertaken to investigate the efficacy, safety, and tolerance of the drug in RS patients. Although during treatment the reduction in duration of Raynaud's attacks was greater in the iloprost group, there were no statistically significant effects. The diary card data demonstrated a high placebo response of 25-30% for this variable. Furthermore, the wide 95% confidence intervals seen in table 3 indicated a high variability of the data-a feature often seen with the duration of attacks in RS. This would have necessitated a change of 60% from baseline in the iloprost group to achieve statistical significance. Conversely, the diary card data demonstrated a near significant result for iloprost for the severity of Raynaud's attacks, with these data showing less variability. This result is supported by the data obtained from the patients' opinions of improvement: the proportion of patients judging their symptoms to be improved was greater in the iloprost group. This difference approached significance at the end of treatment and was statistically significant at the two week follow up visit when the placebo effect in the control group had become attenuated.
Side effects were as expected and were related to the pharmacological properties of iloprost.'7 Despite the number of reported side effects, only three patients felt them to be intolerable and withdrew from the treatment phase. The other patients reduced their drug dosage until the side effects were minimised. Forty percent of patients tolerated the maximum dose, whereas 60% did not. An increase in the maximum dose cannot therefore be suggested in an effort to achieve a greater clinical response. The titration of the dose over three days to a maximum of 150 jig twice daily or best tolerated dose is probably still the best option. The addition of a three times a day dosage schedule for the smallest dose (50 ,ug) might improve the response rate without significantly decreasing tolerance.
In conclusion, iloprost caused a greater reduction in the severity of the attacks and the patients' opinion was also in favour of iloprost over placebo. The effects of iloprost on the total duration of Raynaud's attacks were greater than placebo, but did not reach statistical significance; the high placebo response rate and variability of data probably contributed to this. Furthermore, although this was one of the largest therapeutic studies of RS in SSc, the relatively small numbers may also have led to a type 2 error. Future studies to investigate this compound further should include larger numbers of patients and a three times a day dosage of 50 ,ug.
